Insider Trading Alert - MWE, CPT And CTIC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, June 6, 2014, 96 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,133.00 to $126,311,991.43.

Highlighted Stocks Traded by Insiders:

MarkWest Energy Partners (MWE) - FREE Research Report

Nickerson Randy S, who is EVP, Chief Commercial Officer at MarkWest Energy Partners, sold 3,400 shares at $65.00 on June 6, 2014. Following this transaction, the EVP, Chief Commercial Officer owned 222,309 shares meaning that the stake was reduced by 1.51% with the 3,400-share transaction.

Rosson Paula L, who is SVP/Chief Accounting Officer at MarkWest Energy Partners, sold 1,500 shares at $64.00 on June 6, 2014. Following this transaction, the SVP/Chief Accounting Officer owned 19,924 shares meaning that the stake was reduced by 7% with the 1,500-share transaction.

The shares most recently traded at $64.63, up $0.63, or 0.97% since the insider transaction. Historical insider transactions for MarkWest Energy Partners go as follows:

  • 4-Week # shares bought: 3,850
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 3,850
  • 12-Week # shares sold: 12,521
  • 24-Week # shares bought: 3,850
  • 24-Week # shares sold: 16,751

The average volume for MarkWest Energy Partners has been 840,600 shares per day over the past 30 days. MarkWest Energy Partners has a market cap of $10.3 billion and is part of the basic materials sector and energy industry. Shares are down 2.03% year-to-date as of the close of trading on Friday.

MarkWest Energy Partners, L.P. is engaged in the gathering, processing, and transportation of natural gas. The company is also engaged in the gathering, transportation, fractionation, storage, and marketing of natural gas liquids; and the gathering and transportation of crude oil. The stock currently has a dividend yield of 5.5%. The company has a P/E ratio of 147.2. Currently, there are 3 analysts who rate MarkWest Energy Partners a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MWE - FREE

TheStreet Quant Ratings rates MarkWest Energy Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full MarkWest Energy Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Camden Property (CPT) - FREE Research Report

Sloan Thomas H, who is SVP, Operations at Camden Property, sold 1,000 shares at $71.55 on June 6, 2014. Following this transaction, the SVP, Operations owned 27,502 shares meaning that the stake was reduced by 3.51% with the 1,000-share transaction.

The shares most recently traded at $71.31, down $0.24, or 0.34% since the insider transaction. Historical insider transactions for Camden Property go as follows:

  • 4-Week # shares sold: 13,392
  • 12-Week # shares sold: 37,939
  • 24-Week # shares sold: 72,498

The average volume for Camden Property has been 482,000 shares per day over the past 30 days. Camden Property has a market cap of $6.2 billion and is part of the financial sector and real estate industry. Shares are up 25.39% year-to-date as of the close of trading on Friday.

Camden Property Trust is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It is engaged in the ownership, development, acquisition, management, and disposition of multifamily residential apartment communities. The stock currently has a dividend yield of 3.66%. The company has a P/E ratio of 39.8. Currently, there are 3 analysts who rate Camden Property a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPT - FREE

TheStreet Quant Ratings rates Camden Property as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, good cash flow from operations, impressive record of earnings per share growth and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Camden Property Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cell Therapeutics (CTIC) - FREE Research Report

Bianco James A, who is President and CEO at Cell Therapeutics, sold 55,000 shares at $2.99 on June 6, 2014. Following this transaction, the President and CEO owned 2.3 million shares meaning that the stake was reduced by 2.29% with the 55,000-share transaction.

Plunkett Matthew, who is EVP, Corporate Development at Cell Therapeutics, sold 12,000 shares at $3.02 on June 6, 2014. Following this transaction, the EVP, Corporate Development owned 596,904 shares meaning that the stake was reduced by 1.97% with the 12,000-share transaction.

The shares most recently traded at $3.01, down $0.01, or 0.38% since the insider transaction. Historical insider transactions for Cell Therapeutics go as follows:

  • 4-Week # shares sold: 12,000
  • 12-Week # shares sold: 954,000
  • 24-Week # shares sold: 1.1 million

The average volume for Cell Therapeutics has been 3.7 million shares per day over the past 30 days. Cell Therapeutics has a market cap of $440.5 million and is part of the health care sector and drugs industry. Shares are up 53.93% year-to-date as of the close of trading on Tuesday.

CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer. Currently, there are 3 analysts who rate Cell Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTIC - FREE

TheStreet Quant Ratings rates Cell Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and feeble growth in its earnings per share. Get the full Cell Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook's Investors Have a Big Day Ahead

Facebook's Investors Have a Big Day Ahead

The Global Stock Market Rout Spreads Across the World

The Global Stock Market Rout Spreads Across the World